Literature DB >> 8529326

Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin.

M P Ducharme1, R L Slaughter, L H Warbasse, P H Chandrasekar, V Van de Velde, G Mannens, D J Edwards.   

Abstract

OBJECTIVE: To study the disposition of single doses of phenytoin and itraconazole when administered alone and after chronic treatment with the other drug.
METHODS: Healthy male volunteers were randomized to two groups and studied in parallel. In group 1, a single 200 mg oral dose of itraconazole was administered on two occasions (alone and after 15 days of 300 mg oral phenytoin once daily). Subjects in group 2 were given a single 300 mg oral dose of phenytoin before and after 15 days of itraconazole (200 mg once daily). Blood was collected for 96 hours after each single dose of phenytoin or itraconazole. Serum was assayed for itraconazole and hydroxyitraconazole concentration by HPLC and for phenytoin concentration by fluorescence polarization immunoassay.
RESULTS: Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours. Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours). Itraconazole increased the AUC of phenytoin (10.3%; p < 0.05), with no change in any other pharmacokinetic parameter.
CONCLUSIONS: The striking decrease in itraconazole concentrations with phenytoin is due to induction of metabolism combined with a reduction in the degree of saturable metabolism normally exhibited by itraconazole at this dose. The magnitude of interaction likely accounts for reports of therapeutic failures in patients with fungal infections who are receiving both itraconazole and phenytoin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529326     DOI: 10.1016/0009-9236(95)90017-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 6.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 7.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

8.  Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice.

Authors:  Paul O Gubbins; Bill J Gurley; David K Williams; Scott R Penzak; Scott A McConnell; Amy M Franks; Michael Saccente
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

9.  Assessment of inter-individual variability in predicted phenytoin clearance.

Authors:  Thomas M Polasek; Sebastian Polak; Matthew P Doogue; Amin Rostami-Hodjegan; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

10.  Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.

Authors:  Susan M Abdel-Rahman; Richard F Jacobs; Joseph Massarella; Ralph E Kauffman; John S Bradley; Hui C Kimko; Gregory L Kearns; Kevin Shalayda; Christopher Curtin; Samuel D Maldonado; Jeffrey L Blumer
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.